Maynard Um
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) PT Lowered to $64 at Truist Securities
-
-
-
-
-
-
-
Mizuho on Maze Therapeutics (MAZE): top-line data from Ph2 study shows 'best-in-class' potential
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Maze Therapeutics (MAZE)
-
-
-
-
-
-
-
Maze Therapeutics (MAZE) files for 9.23M share offering by selling stockholders
-
-
-
-
-
-
-
BTIG Starts Maze Therapeutics (MAZE) at Buy
-
-
-
-
-
-
-
JPMorgan Starts Maze Therapeutics (MAZE) at Overweight
-
-
-
466,298 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


